Predictive biomarkers of response to tocilizumab in giant cell arteritis (GCA): correlations with imaging activity-Reference-Cited by-同舟云学术

Predictive biomarkers of response to tocilizumab in giant cell arteritis (GCA): correlations with imaging activity

Published:2024-08-30 Issue: Volume: Page:
ISSN:0257-277X
Container-title:Immunologic Research
language:en
Short-container-title:Immunol Res

Author:

Benucci Maurizio,Di Girolamo Ilaria,Di Girolamo Antonino,Gobbi Francesca Li,Damiani Arianna,Guiducci Serena,Lari Barbara,Grossi Valentina,Infantino Maria,Manfredi Mariangela

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12026-024-09518-0.pdf

Reference29 articles.

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11. https://doi.org/10.1002/art.37715.

2. Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol. 2008;35:88–95. https://doi.org/10.1007/s12016-008-8075-0.

3. Dejaco C, Duftner C, Buttgereit F, Matteson EL. Dasgupta B et al The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatol Oxf Engl. 2017;56:506–15. https://doi.org/10.1093/rheumatology/kew273.

4. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19–30. https://doi.org/10.1136/annrheumdis-2019-215672.

5. Valent F, Bond M, Cavallaro E, Treppo E, Rosalia Maria DR, Tullio A, Dejaco C, De Vita S. Data linkage analysis of giant cell arteritis in Italy: healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017). Quartuccio Vasc Med Lond Engl. 2020;25(2):150–6. https://doi.org/10.1177/1358863X19886074.